EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Clinical trial: A Mediterranean diet is feasible and improves gastrointestinal and psychological symptoms in irritable bowel syndrome

Heidi M Staudacher iD, Sophie Mahoney, Kim Canale, Rachelle S Opie, Amy Loughman, Daniel So iD, Lauren Beswick, Chris Hair, Felice N Jacka

Alimentary Pharmacology & Therapeutics · 2024-02 · 59 (4) · 492-503

DOI: 10.1111/apt.17791 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 15.11.2023. Verfasst von Heidi M Staudacher und 8 weiteren Autor:innen. Beteiligte Einrichtung: Food & Mood Centre, The Institute for Mental and Physical Health and Clinical Translation (IMPACT), School of Medicine and Barwon Health, Deakin Univ…. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Diet, Mediterranean, Microbiota. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Alfred Deakin Postdoctoral Research Fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diet is fundamental to the care of irritable bowel syndrome (IBS). However, some approaches are not appropriate for individuals experiencing psychological symptoms.

Aims

To assess feasibility of a Mediterranean diet in IBS and its impact on gastrointestinal and psychological symptoms.

Methods

We recruited adults with Rome IV IBS and mild or moderate anxiety and/or depressive symptoms to an unblinded 6‐week randomised controlled trial. Patients were randomised to Mediterranean diet counselling or habitual diet. We collected gastrointestinal and psychological symptom data, dietary data and stool samples for metagenomic sequencing.

Results

We randomised 59 individuals (29 Mediterranean diet, 30 control); 48 completed the study. The Mediterranean Diet Adherence Screener score was higher in the Mediterranean diet group than controls at week 6 (7.5 [95% CI: 6.9–8.0] vs. 5.7 [5.2–6.3], p < 0.001), and there was a greater score increase than controls (2.1 [95% CI: 1.3–2.9] vs. 0.5 [95% CI: 0.1–1.0], p = 0.004), demonstrating Mediterranean diet feasibility. There was a greater proportion of gastrointestinal symptom responders in the Mediterranean diet group than controls (24/29, 83% vs. 11/30, 37%, p < 0.001) and depression responders (15/29, 52% vs. 6/30 20%, p = 0.015). There was no difference in FODMAP intake at week 6 ( p = 0.51). Gastrointestinal adverse events were similar ( p = 0.588). There were no differences in change in microbiome parameters between groups.

Conclusions

A Mediterranean diet is feasible in IBS and leads to improvement in gastrointestinal and psychological symptoms. Although this study was unblinded, these findings together with the broader benefits of the Mediterranean diet, provide strong impetus for future research in IBS. Australia New Zealand Clinical Trials Registry: ACTRN12620001362987.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Irritable Bowel SyndromeDiet, MediterraneanMicrobiotaAdultHumansDisaccharidesMonosaccharidesDietFermentation

Stichwörter der Autor:innen

irritable bowel syndrome < disease-basedmicrobiome < topicsnutrition < topicspsychiatric disorders < topics

Substanzen

DisaccharidesMonosaccharides

Autor:innen und Institutionen

  • Food & Mood Centre, The Institute for Mental and Physical Health and Clinical Translation (IMPACT), School of Medicine and Barwon Health, Deakin University, Geelong, Victoria, Australia.
  • Department of Nutritional Sciences, King's College London, London, UK.
  • Department of Gastroenterology, Barwon Health, Geelong, Victoria, Australia.
  • School of Medicine, Deakin University, Geelong, Victoria, Australia.
  • Centre for Adolescent Health, Murdoch Children's Research Institute, Parkville, Victoria, Australia.

ORCID-Profile: Heidi M Staudacher, Daniel So

Förderung

  • Alfred Deakin Postdoctoral Research Fellowship

Zitieren

APA

Staudacher, H. M., Mahoney, S., Canale, K., Opie, R. S., Loughman, A., So, D., Beswick, L., Hair, C., & Jacka, F. N. (2024). Clinical trial: A Mediterranean diet is feasible and improves gastrointestinal and psychological symptoms in irritable bowel syndrome. Alimentary Pharmacology & Therapeutics, 59(4), 492-503. https://doi.org/10.1111/apt.17791

Vancouver

Staudacher HM, Mahoney S, Canale K, Opie RS, Loughman A, So D, et al. Clinical trial: A Mediterranean diet is feasible and improves gastrointestinal and psychological symptoms in irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. 2024;59(4):492-503. doi:10.1111/apt.17791

BibTeX
@article{Staudacher2024,
  author = {Staudacher, Heidi M and Mahoney, Sophie and Canale, Kim and Opie, Rachelle S and Loughman, Amy and So, Daniel and Beswick, Lauren and Hair, Chris and Jacka, Felice N},
  title = {Clinical trial: A Mediterranean diet is feasible and improves gastrointestinal and psychological symptoms in irritable bowel syndrome},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  volume = {59},
  number = {4},
  pages = {492--503},
  doi = {10.1111/apt.17791}
}
Kostenlos starten →